Cas no 1015845-70-1 (1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine)
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine Chemical and Physical Properties
Names and Identifiers
-
- 1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine
- 1-(3-chlorobenzyl)-4-methyl-1H-pyrazol-5-amine(SALTDATA: FREE)
- 2-[(3-chlorophenyl)methyl]-4-methylpyrazol-3-amine
- AG-D-08665
- Ambcb4022399
- CTK3J9933
- KB-213760
- MolPort-004-961-641
- CHEMBRDG-BB 4022399
- 2-(3-CHLORO-BENZYL)-4-METHYL-2H-PYRAZOL-3-YLAMINE
- 1-[(3-CHLOROPHENYL)METHYL]-4-METHYL-1H-PYRAZOL-5-AMINE
- 1H-Pyrazol-5-amine, 1-[(3-chlorophenyl)methyl]-4-methyl-
-
- MDL: MFCD08457374
- Inchi: InChI=1S/C11H12ClN3/c1-8-6-14-15(11(8)13)7-9-3-2-4-10(12)5-9/h2-6H,7,13H2,1H3
- InChI Key: UWNPINHVNXBRAD-UHFFFAOYSA-N
- SMILES: CC1=C(N)N(CC2=CC(=CC=C2)Cl)N=C1
Computed Properties
- Exact Mass: 221.07200
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 3
- Heavy Atom Count: 15
- Rotatable Bond Count: 2
Experimental Properties
- PSA: 43.84000
- LogP: 3.05660
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine Customs Data
- HS CODE:2933199090
- Customs Data:
China Customs Code:
2933199090Overview:
2933199090. Other structurally non fused pyrazole ring compounds. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to, Please indicate the appearance of Urotropine, 6- caprolactam please indicate the appearance, Signing date
Summary:
2933199090. other compounds containing an unfused pyrazole ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | C364898-50mg |
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine |
1015845-70-1 | 50mg |
$ 50.00 | 2022-06-01 | ||
| TRC | C364898-100mg |
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine |
1015845-70-1 | 100mg |
$ 65.00 | 2022-06-01 | ||
| TRC | C364898-500mg |
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine |
1015845-70-1 | 500mg |
$ 80.00 | 2022-06-01 | ||
| abcr | AB215904-1 g |
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine; 95% |
1015845-70-1 | 1g |
€128.10 | 2023-02-05 | ||
| abcr | AB215904-5 g |
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine; 95% |
1015845-70-1 | 5g |
€365.50 | 2023-02-05 | ||
| eNovation Chemicals LLC | Y1240911-5g |
1H-Pyrazol-5-amine, 1-[(3-chlorophenyl)methyl]-4-methyl- |
1015845-70-1 | 95% | 5g |
$355 | 2023-05-18 | |
| abcr | AB215904-1g |
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine, 95%; . |
1015845-70-1 | 95% | 1g |
€137.20 | 2025-02-27 | |
| abcr | AB215904-5g |
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine, 95%; . |
1015845-70-1 | 95% | 5g |
€381.90 | 2025-02-27 | |
| A2B Chem LLC | AA06115-1g |
1H-Pyrazol-5-amine, 1-[(3-chlorophenyl)methyl]-4-methyl- |
1015845-70-1 | 95% | 1g |
$120.00 | 2024-04-20 | |
| A2B Chem LLC | AA06115-5g |
1H-Pyrazol-5-amine, 1-[(3-chlorophenyl)methyl]-4-methyl- |
1015845-70-1 | 95% | 5g |
$445.00 | 2024-04-20 |
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine Suppliers
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine Related Literature
-
Ravi Kumar Yadav,R. Govindaraj Phys. Chem. Chem. Phys., 2020,22, 26876-26886
-
Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
-
Cheng Fang,Jinjian Wu,Zahra Sobhani,Md. Al Amin,Youhong Tang Anal. Methods, 2019,11, 163-170
-
Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
-
Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
Additional information on 1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine
Research Briefing on 1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine (CAS: 1015845-70-1)
1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine (CAS: 1015845-70-1) is a pyrazole derivative that has garnered significant attention in recent chemical and pharmaceutical research due to its potential as a bioactive scaffold. This compound belongs to a class of heterocyclic amines known for their diverse pharmacological properties, including anti-inflammatory, antimicrobial, and anticancer activities. Recent studies have focused on its synthesis, structural optimization, and biological evaluation, positioning it as a promising candidate for drug development.
The compound's molecular structure features a chlorobenzyl group at the 1-position and a methyl group at the 4-position of the pyrazole ring, which contributes to its unique chemical reactivity and binding affinity. Researchers have explored its role as an intermediate in the synthesis of more complex molecules, particularly in the development of kinase inhibitors and G-protein-coupled receptor (GPCR) modulators. Its mechanism of action is believed to involve interference with key signaling pathways, making it a subject of interest in targeted therapy research.
Recent publications highlight advancements in the synthetic routes for 1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine, with emphasis on improving yield and purity. Green chemistry approaches, such as solvent-free reactions and catalytic methods, have been successfully applied to its production. Additionally, computational studies, including molecular docking and quantitative structure-activity relationship (QSAR) analyses, have provided insights into its binding modes and potential therapeutic targets.
In vitro and in vivo studies have demonstrated the compound's efficacy in various disease models. For instance, it has shown inhibitory activity against specific cancer cell lines by inducing apoptosis and cell cycle arrest. Its anti-inflammatory properties have been linked to the suppression of pro-inflammatory cytokines, suggesting potential applications in autoimmune and chronic inflammatory conditions. However, further pharmacokinetic and toxicological evaluations are necessary to assess its clinical viability.
The current research landscape underscores the need for multidisciplinary collaboration to fully exploit the therapeutic potential of 1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine. Future directions may include structural modifications to enhance bioavailability, combination studies with existing drugs, and the development of novel formulations. As the understanding of its biological interactions deepens, this compound could pave the way for innovative treatments in oncology, immunology, and infectious diseases.
1015845-70-1 (1-(3-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine) Related Products
- 30153-85-6(1-(4-Chlorobenzyl)-1H-pyrazol-5-amine)
- 3524-28-5(1-(2-Chlorobenzyl)-1H-pyrazol-5-amine)
- 925154-93-4(1-(4-chlorobenzyl)-1H-pyrazol-3-amine)
- 956440-15-6(1-(3-chlorophenyl)methyl-1H-pyrazol-5-amine)
- 3528-49-2(1-Benzyl-4-methyl-1H-pyrazol-5-amine)
- 1015845-62-1(4-Methyl-1-(3-methylbenzyl)-1H-pyrazol-5-amine)
- 1015845-68-7(1-(2-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine)
- 106898-40-2(1-(2,4-dichlorobenzyl)-5-amino-1H-pyrazole-4-carbonitrile)
- 895929-56-3(1-(3,4-dichlorobenzyl)-1h-pyrazol-3-amine)
- 1015846-01-1(1-(4-Chlorobenzyl)-4-methyl-1H-pyrazol-5-amine)